Compare SKYW & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYW | CRNX |
|---|---|---|
| Founded | 1972 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.9B |
| IPO Year | 1994 | 2018 |
| Metric | SKYW | CRNX |
|---|---|---|
| Price | $83.69 | $38.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $123.67 | $76.75 |
| AVG Volume (30 Days) | 349.6K | ★ 971.8K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.20 | N/A |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $2,971,963,000.00 | $1,039,000.00 |
| Revenue This Year | $8.35 | $720.10 |
| Revenue Next Year | $3.55 | $184.67 |
| P/E Ratio | $33.02 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $80.00 | $25.83 |
| 52 Week High | $123.94 | $57.99 |
| Indicator | SKYW | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 37.51 | 51.30 |
| Support Level | N/A | $33.19 |
| Resistance Level | $102.83 | $45.32 |
| Average True Range (ATR) | 3.30 | 1.47 |
| MACD | -1.28 | 0.00 |
| Stochastic Oscillator | 16.51 | 40.75 |
SkyWest Inc offers commercial air services in the United States, Canada, Mexico, and the Caribbean. Additionally, it leases aircraft to capable users to help generate revenue. SkyWest generally provides regional flights and utilizes smaller, lower-cost aircraft to carry passengers who book tickets through partner airlines. It partners with carriers to fly and operate aircraft for a fee and may use the carriers' brands and ground support to coordinate marketing and transport passengers. The company has two reportable segments: SkyWest Airlines and SWC, which generate maximum revenue, and SkyWest Leasing activities.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.